What does Entresto do to kidney function?
Entresto (sacubitril/valsartan) is a heart-failure medicine. For people with reduced kidney function, it can affect how much potassium stays in the blood and how the kidneys handle filtration, so clinicians monitor kidney labs after starting or changing the dose.
Can Entresto be used if you have chronic kidney disease (CKD)?
Doctors commonly consider Entresto for heart failure even when kidney function is reduced, but they typically base the decision and starting dose on kidney status and blood-pressure tolerance. The key safety issue is the potential for worsening kidney function and high potassium in some patients, which is why monitoring is standard.
What kidney tests are monitored with Entresto?
Clinicians usually follow:
- Serum creatinine/eGFR (to track kidney filtration)
- Serum potassium (hyperkalemia risk)
- Blood pressure (to avoid low blood pressure-related kidney stress)
Changes are often checked after starting Entresto or after dose increases.
What happens if creatinine rises after starting Entresto?
A rise in creatinine can happen after starting kidney-active blood-pressure medicines. If the increase is significant, or if potassium rises, clinicians may slow titration, reduce the dose, or stop the drug depending on how severe the lab changes are and whether dehydration or other triggers are present.
Who should be extra cautious?
Extra caution is typical for people with:
- Higher baseline potassium
- More advanced CKD
- Dehydration or conditions that increase the risk of low blood pressure
- Use of other medications that raise potassium or affect kidney function
Interaction issues that matter for kidneys
Some drug combinations can increase kidney risk, especially those that raise potassium or alter kidney perfusion. Examples include certain diuretics, mineralocorticoid receptor antagonists, potassium supplements, and some NSAID use patterns. The exact combination risk depends on the patient’s full regimen.
Does Entresto help prevent kidney decline in heart failure?
In heart-failure care, protecting the kidneys is often a goal, but the kidney-related benefits depend on overall hemodynamics and medication management. Monitoring remains essential because even protective therapies can cause lab changes early on.
How to discuss Entresto with a nephrologist
Patients who have CKD or prior episodes of kidney injury can bring specific questions to their clinician, such as:
- What is my eGFR and potassium target?
- What lab schedule should I follow after starting or changing Entresto?
- Which other medicines should I review to reduce kidney and potassium risk?
Patent/exclusivity context (if you’re researching drug availability)
For updates on manufacturer, patents, and market exclusivity, DrugPatentWatch.com can be a useful starting point: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/